Baseline disease history in JAK2p.V617F-positive patients by tertile
| . | Tertile 1 (−100% to ≤−24.66%) (n = 36) . | Tertile 2 (>−24.66% to ≤−8%) (n = 36) . | Tertile 3 (>−8%) (n = 35) . |
|---|---|---|---|
| Maximum percent change in allele burden | |||
| Mean | −62.6 | −15.3 | −0.5 |
| Median | −63.4 | −14.8 | −2.2 |
| Baseline allele burden | |||
| Mean | 70.9 | 73.5 | 75.3 |
| Median | 84.5 | 81.5 | 84.0 |
| Duration of disease prior to treatment, months | |||
| Mean | 36.8 | 52.5 | 44.8 |
| Median | 15.2 | 21.7 | 22.1 |
| Tumor type, n (%) | |||
| Post-ET MF | 4 (11.1) | 5 (13.9) | 10 (28.6) |
| Post-PV MF | 17 (47.2) | 17 (47.2) | 15 (42.9) |
| PMF | 15 (41.7) | 14 (38.9) | 10 (28.6) |
| IPSS risk level*at screening, n (%) | |||
| High risk | 15 (41.7) | 21 (60.0) | 27 (77.1) |
| Intermediate-2 risk | 21 (58.3) | 14 (40.0) | 8 (22.9) |
| . | Tertile 1 (−100% to ≤−24.66%) (n = 36) . | Tertile 2 (>−24.66% to ≤−8%) (n = 36) . | Tertile 3 (>−8%) (n = 35) . |
|---|---|---|---|
| Maximum percent change in allele burden | |||
| Mean | −62.6 | −15.3 | −0.5 |
| Median | −63.4 | −14.8 | −2.2 |
| Baseline allele burden | |||
| Mean | 70.9 | 73.5 | 75.3 |
| Median | 84.5 | 81.5 | 84.0 |
| Duration of disease prior to treatment, months | |||
| Mean | 36.8 | 52.5 | 44.8 |
| Median | 15.2 | 21.7 | 22.1 |
| Tumor type, n (%) | |||
| Post-ET MF | 4 (11.1) | 5 (13.9) | 10 (28.6) |
| Post-PV MF | 17 (47.2) | 17 (47.2) | 15 (42.9) |
| PMF | 15 (41.7) | 14 (38.9) | 10 (28.6) |
| IPSS risk level*at screening, n (%) | |||
| High risk | 15 (41.7) | 21 (60.0) | 27 (77.1) |
| Intermediate-2 risk | 21 (58.3) | 14 (40.0) | 8 (22.9) |
IPSS, international prognostic scoring system; PMF, primary myelofibrosis.
Cervantes et al.18